Skip to main content
SpringerLink
Log in

P-Glycoprotein Inhibition Leads to Enhanced Disruptive Effects by Anti-Microtubule Cytostatics at the In Vitro Blood-Brain Barrier

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. To investigate whether P–glycoprotein (Pgp) protects the in vitro BBB against the cytotoxic effects of anti–tumour drugs.

Methods. In an in vitro BBB coculture model the influence of the anti–microtubule drugs vinblastine, colchicine, paclitaxel and the non–antimicrotubule drugs doxorubicin, fluorouracil and etoposide in the absence or presence of Pgp modulators on the trans–endothelial electrical resistance (TEER), which is an indicator for the integrity, was investigated.

Results. In the absence of Pgp modulators vinblastine, colchicine and paclitaxel dose dependently decreased TEER values to less than 20% of control. Non–anti–microtubule drugs did not affect TEER values. Following competitive inhibition of Pgp by various Pgp modulators and substrates, even low concentrations of vinblastine, colchicine and paclitaxel substantially decreased TEER. IC50 values of LY 335979, SDZ–PSC 833, cyclosporin A, and verapamil were 0.03, 0.25, 0.46, and 13.7 μM, respectively.

Conclusions. These results indicate that Pgp normally protects the in vitro BBB against the disruptive effects of anti–microtubule drugs, but its integrity is lost when anti–microtubule drugs are used in combination with potent Pgp modulators. In addition, this procedure offers the possibility to characterize Pgp modulators and substrates with respect to their efficacy and to elucidate drug interactions at the level of Pgp.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. M. Bradbury. The concept of the blood–brain barrier, John Wiley and Sons, Chichester, 1979.

    Google Scholar 

  2. W. M. Pardridge. Knocking on the cerebral door; a challenge for CNS drug development, Odessey 1:46–51 (1995).

    Google Scholar 

  3. H. E. de Vries, J. Kuiper, A. G. de Boer, T. J. van Berkel, and D. D. Breimer. The blood–brain barrier in neuroinflammatory diseases. Pharmacol. Rev. 49:143–155 (1997).

    Google Scholar 

  4. C. Cordon–Cardo, J. P. O'Brien, D. Casals, L. Rittman–Grauer, J. L. Biedler, M. R. Melamed, and J. R. Bertino. Multidrug resistance gene (P–glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc. Natl. Acad. Sci. USA 86:695–698 (1989).

    Google Scholar 

  5. N. Kartner, J. R. Riordan, and V. Ling. Cell surface P–glycoprotein associated with multidrug resistance in mammalian cells. Science 221:1285–1288 (1983).

    Google Scholar 

  6. J. Robert. Approaches to multidrug resistance reversal. Exp. Opin. Invest. Drugs 7:929–939 (1998).

    Google Scholar 

  7. J. Wijnholds, G. L. Scheffer, M. van der Valk, P. van der Valk, J. H. Beijnen, R. J. Scheper, and P. Borst. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug–induced damage. J. Exp. Med. 188:797–808 (1998)

    Google Scholar 

  8. P. J. Gaillard, I. C. van der Sandt, L. H. Voorwinden, D. Vu, J. Nielsen, A. G. de Boer, and D. D. Breimer. Astrocytes increase the functional expression of P–glycoprotein in an vitro model of the blood–brain barrier. Pharm. Res. 17:1198–1205 (2000).

    Google Scholar 

  9. P. J. Gaillard, A. G. de Boer, and D. D. Breimer. Relationship between permeability status of the blood–brain barrier and in vitro permeability coefficient of a drug. Pharm. Res. 12:95–102 (1995).

    Google Scholar 

  10. P. J. Gaillard, L. H. Voorwinden, J. Nielsen, A. Ivanov, R. Atsumi, H. Engman, C. Ringbom, A. G. de Boer, and D. D. Breimer. Establishment and functional characterization of an in vitro model of the blood–brain barrier, comprising a coculture of brain capillary endothelial cells and astrocytes. Eur. J. Pharm. Sci. 12:215–222 (2001).

    Google Scholar 

  11. A. H. Schinkel, E. Wagenaar, L. van Deemter, C. A. Mol, and P. Borst. Absence of the mdr1a P–glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1698–705 (1995).

    Google Scholar 

  12. J. W. Jonker, E. Wagenaar, L. van Deemter, R. Gottschlich, H. M. Bender, J. Dasenbrock, and A. H. Schinkel. Role of blood–brain barrier P–glycoprotein in limiting brain accumulation and sedative side–effects of asimadoline, a peripherally acting analgesic drug. Br. J. Pharm. 127:43–50 (1999).

    Google Scholar 

  13. S. P. Letrent, G. M. Pollack, K. R. Brouwer, and K. L. Brouwer. Effects of a potent and specific P–glycoprotein inhibitor on the blood–brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab. Dispos. 27:827–834 (1999).

    Google Scholar 

  14. L. Wilson and M. A. Jordan. Microtubule dynamics: taking aim at a moving target. Chem. Biol. 2:569–573 (1995).

    Google Scholar 

  15. D. T. Hung, T. F. Jamison, and S. L. Schreiber. Understanding and controlling the cell cycle with natural products. Chem. Biol. 3:623–639 (1996).

    Google Scholar 

  16. P. K. Sorger, M. Dobles, R. Tournebize, and A. A. Hyman. Coupling cell division and cell death to microtubule dynamics. Current Opinion in Cell Biology. 9:807–814 (1997).

    Google Scholar 

  17. M. A. Jordan, D. Thrower, and L. Wilson. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 51:2212–2222 (1991).

    Google Scholar 

  18. M. A. Jordan, R. J. Toso, D. Thrower, and L. Wilson. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. USA. 90:9952–9556 (1993).

    Google Scholar 

  19. J. F. Diaz and J. M. Andreu. Kinetics of dissociation of the tubulin–colchicine complex. J. Biol. Chem. 266:2890–2896 (1991).

    Google Scholar 

  20. C. Mouchard–Delmas, B. Gourdier, R. Vistelle, and M. Wiczewski. Modification of the blood–brain barrier permeability following intracarotid infusion of vinorelbine. Anticancer Res. 15:2593–2596 (1995).

    Google Scholar 

  21. S. Nag. Role of the endothelial cytoskeleton in blood–brain–barrier permeability to protein. Acta Neuropathol. 90:454–460 (1995).

    Google Scholar 

  22. G. M. Ferron, M. Rochdi, W. J. Jusko, and J. M. Scherrmann. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J. Clin. Pharmacol. 36:874–883 (1996).

    Google Scholar 

  23. M. T. Huizing, J. B. Vermorken, H. Rosing, W. W. ten Bokkel–Huinink, I. Mandjes, H. M. Pinedo, and J. H. Beijnen. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3–hour paclitaxel infusion: A European Cancer Centre (ECC) trial. Ann. Oncol. 6:699–704 (1995).

    Google Scholar 

  24. R. Rahmani, J. P. Kleisbauer, J. P. Cano, M. Martin, and J. Barbet. Clinical pharmacokinetics of vindesine infusion. Cancer Treat. Rep. 69:839–844 (1985).

    Google Scholar 

  25. J. M. Ford. Modulators of multidrug resistance, Drug Res. Clin. Oncol. Hematol. 9:337–361 (1995).

    Google Scholar 

  26. G. A. Fisher, B. L. Lum, and B. I. Sikic. The reversal of multidrug resistance. Cancer. Treat. Res. 78:45–70 (1995).

    Google Scholar 

  27. R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter P–glycoprotein limits oral absorption and brain entry of HIV–1 protease inhibitors. J. Clin. Invest. 101:289–294 (1998).

    Google Scholar 

  28. I. C. van der Sandt, C. M. Vos, L. Nabulsi, M. C. Blom–Roosemalen, H. H. Voorwinden, A. G. de Boer, and D. D. Breimer. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood–brain barrier. AIDS 15:483–491 (2001).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leiden/Amsterdam Center for Drug Research, Division of Pharmacology, Leiden University, P.O. Box 9503, 2300 RA, Leiden, The Netherlands

    Inez C. J. van der Sandt, Pieter J. Gaillard, Heleen H. Voorwinden, Albertus G. de Boer & Douwe D. Breimer

Authors
  1. Inez C. J. van der Sandt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pieter J. Gaillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heleen H. Voorwinden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Albertus G. de Boer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Douwe D. Breimer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Sandt, I.C.J., Gaillard, P.J., Voorwinden, H.H. et al. P-Glycoprotein Inhibition Leads to Enhanced Disruptive Effects by Anti-Microtubule Cytostatics at the In Vitro Blood-Brain Barrier. Pharm Res 18, 587–592 (2001). https://doi.org/10.1023/A:1011016923346

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011016923346

Search

Navigation